Find More Contacts for Vertex Pharmaceuticals
Protected Content
General Counsel
Non-Management, Executive Legal, Management
2 emails found
View contacts for Vertex Pharmaceuticals to access new leads and connect with decision-makers.
View All Contacts
  • Number of Exits 
  • Contact Email mediainfo@vrtx.com
  • Phone Number 617-341-6100

Vertex Pharmaceuticals is a biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases,

cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

Lists Featuring This Company

New England Public Companies With More Than $500 in Revenue
132 Number of Organizations â€¢ $130.9B Total Funding Amount â€¢ 334 Number of Investors
Health Care Public Companies With More Than $1M in Revenue
1,896 Number of Organizations â€¢ $522.9B Total Funding Amount â€¢ 6,577 Number of Investors
Boston Investors
855 Number of Organizations â€¢ $38.6B Total Funding Amount â€¢ 545 Number of Investors
Massachusetts Companies With More Than $100M in Revenue
996 Number of Organizations â€¢ $152.7B Total Funding Amount â€¢ 1,687 Number of Investors

Frequently Asked Questions

Where is Vertex Pharmaceuticals's headquarters? Vertex Pharmaceuticals is located in Boston, Massachusetts, United States.Who invested in Vertex Pharmaceuticals? Vertex Pharmaceuticals has 9 investors including J.P. Morgan Securities Inc. and Bank of America Merrill Lynch.How much funding has Vertex Pharmaceuticals raised to date? Vertex Pharmaceuticals has raised .When was the last funding round for Vertex Pharmaceuticals? Vertex Pharmaceuticals closed its last funding round on May 17, 2022 from a Post-IPO Equity round.Who are Vertex Pharmaceuticals's competitors? Alternatives and possible competitors to Vertex Pharmaceuticals may include Ionis PharmaceuticalsUltragenyx Pharmaceutical, and Merck.